Gastroenterology Research and Practice最新文献_第10页

Effect of Early Continuous Veno-Venous Haemofiltration in Severe Acute Pancreatitis for the Prevention of Local Pancreatic Complications 重症急性胰腺炎早期持续静脉-静脉血液滤过对预防局部胰腺并发症的作用

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice

Pub Date : 2022-03-07 DOI: 10.1155/2022/7575231

S. Yadav, Bing Zhang

Objective To compare the conventional treatment and continuous veno-venous haemofiltration (CVVH) in severe acute pancreatitis (SAP) for the prevention of pseudocyst and walled-off necrosis. Patients and Methods. Forty-two patients were divided into two treatment groups: conventional treatment group contained 24 patients and CVVH had 18. Conventional treatment group patients were treated symptomatically and according to the causes. CVVH group patients were treated symptomatically, and CVVH was done within 2 hours of admission. Results In both groups, there was a decrease in amylase, lipase, CRP, IL-6, IL-10, TNF-alpha, Ranson score, Balthazar score, and APACHE-II score after 72 hours, but the decrease was significantly greater in CVVH patients. There were no any local pancreatic complications in CVVH patients, but 1 patient had an acute peripancreatic fluid collection, 2 patients had pseudocyst, and 2 patients had walled-off necrosis (WON), and a mortality one was seen in the conventional treatment group. Conclusion The present study shows that early CVVH may be able to prevent the formation of pseudocyst and win in SAP patients.

目的比较常规治疗和连续静脉-静脉血液滤过（CVVH）治疗重症急性胰腺炎（SAP）预防假性囊肿和坏死的疗效。患者和方法。42例患者分为两组：常规治疗组24例，CVVH组18例。常规治疗组患者根据症状和病因进行治疗。CVVH组患者接受症状治疗，并在入院后2小时内进行CVVH。结果72小时后，两组患者的淀粉酶、脂肪酶、CRP、IL-6、IL-10、TNF-α、Ranson评分、Balthazar评分和APACHE-II评分均下降，但CVVH患者的下降幅度更大。CVVH患者没有任何胰腺局部并发症，但1例患者出现急性胰周积液，2例患者出现假性囊肿，2例出现壁坏死（WON），常规治疗组出现1例死亡。结论早期CVVH可预防SAP患者假性囊肿的形成，有利于SAP患者的生存。

{"title":"Effect of Early Continuous Veno-Venous Haemofiltration in Severe Acute Pancreatitis for the Prevention of Local Pancreatic Complications","authors":"S. Yadav, Bing Zhang","doi":"10.1155/2022/7575231","DOIUrl":"https://doi.org/10.1155/2022/7575231","url":null,"abstract":"Objective To compare the conventional treatment and continuous veno-venous haemofiltration (CVVH) in severe acute pancreatitis (SAP) for the prevention of pseudocyst and walled-off necrosis. Patients and Methods. Forty-two patients were divided into two treatment groups: conventional treatment group contained 24 patients and CVVH had 18. Conventional treatment group patients were treated symptomatically and according to the causes. CVVH group patients were treated symptomatically, and CVVH was done within 2 hours of admission. Results In both groups, there was a decrease in amylase, lipase, CRP, IL-6, IL-10, TNF-alpha, Ranson score, Balthazar score, and APACHE-II score after 72 hours, but the decrease was significantly greater in CVVH patients. There were no any local pancreatic complications in CVVH patients, but 1 patient had an acute peripancreatic fluid collection, 2 patients had pseudocyst, and 2 patients had walled-off necrosis (WON), and a mortality one was seen in the conventional treatment group. Conclusion The present study shows that early CVVH may be able to prevent the formation of pseudocyst and win in SAP patients.","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49218864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Transanal versus Laparoscopic Total Mesorectal Excision in Male Patients with Low Tumor Location after Neoadjuvant Therapy: A Propensity Score-Matched Cohort Study 新辅助治疗后肿瘤位置低的男性患者经肛门与腹腔镜全直肠系膜切除术：倾向评分匹配的队列研究

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice

Pub Date : 2022-02-27 DOI: 10.1155/2022/2387464

Ze Li, Jingkun Xiao, Y. Hou, Xing-wei Zhang, H. Jie, Huashan Liu, Lei Ruan, Z. Zeng, L. Kang

Background Since Sylla and Lacy successfully reported the transanal total mesorectal excision in 2010, taTME was considered to have the potential to overcome some problematic laparoscopic cases in male, low advanced rectal cancer. However, the evidence is still lacking. This study compared the short and long outcomes of taTME with laTME in these “challenging” patients to explore the advantages of taTME among the patients. Method After propensity score matching analysis, 106 patients were included in each group from 325 patients who met the including standard. Statistical analysis was used to compare the differences of perioperative outcomes, histopathological results, and survival results between taTME and laTME groups. Results The mean time of pelvic operation in the taTME group was significantly shorter than in the laTME group (62.2 ± 14.2 mins vs 81.1 ± 18.9 mins, P = 0.003). The complication incidence rate and the rate of protective loop ileostomy in the taTME group were significantly lower than those in the laTME group (19.8% vs 38.7%, P = 0.003 and 70.8% vs 92.5%, P < 0.001). In long-term result, there was no significant difference between the two groups for 3-year OS (87.3% vs 85.4%, P = 0.86) or 3-year DFS (74.9% vs 70.1%, P = 0.92). The 2-year cumulative local recurrence rate was similar between the two groups (1.1% vs 5.8%, P = 0.22). Conclusion This study demonstrated that taTME might reduce the incidence of postoperative complications, especially of anastomotic leakage in these “challenging” patients. taTME may be considered to have clear advantages for “challenging” patients.

背景自从Sylla和Lacy在2010年成功报道经肛门全直肠炎切除术以来，taTME被认为有可能克服男性低晚期癌症中一些有问题的腹腔镜病例。然而，证据仍然缺乏。本研究比较了taTME和laTME在这些“具有挑战性”患者中的短期和长期结果，以探索taTME在患者中的优势。方法对325例符合纳入标准的患者进行倾向评分匹配分析，每组106例。统计分析用于比较taTME组和laTME组的围手术期结果、组织病理学结果和生存率结果的差异。结果taTME组盆腔手术平均时间明显短于laTME组（62.2±14.2分钟vs 81.1±18.9分钟，P=0.003），并发症发生率和保护环回肠造口术发生率明显低于laTME（19.8%vs 38.7%，P=0.003和70.8%vs 92.5%，P<0.001），两组3年OS（87.3%vs 85.4%，P=0.86）和3年DFS（74.9%vs 70.1%，P=0.92）无显著差异。两组2年累积局部复发率相似（1.1%vs 5.8%，P=0.22），尤其是这些“有挑战性”的患者的吻合口瘘。taTME可能被认为对“有挑战性”的患者有明显的优势。

{"title":"Transanal versus Laparoscopic Total Mesorectal Excision in Male Patients with Low Tumor Location after Neoadjuvant Therapy: A Propensity Score-Matched Cohort Study","authors":"Ze Li, Jingkun Xiao, Y. Hou, Xing-wei Zhang, H. Jie, Huashan Liu, Lei Ruan, Z. Zeng, L. Kang","doi":"10.1155/2022/2387464","DOIUrl":"https://doi.org/10.1155/2022/2387464","url":null,"abstract":"Background Since Sylla and Lacy successfully reported the transanal total mesorectal excision in 2010, taTME was considered to have the potential to overcome some problematic laparoscopic cases in male, low advanced rectal cancer. However, the evidence is still lacking. This study compared the short and long outcomes of taTME with laTME in these “challenging” patients to explore the advantages of taTME among the patients. Method After propensity score matching analysis, 106 patients were included in each group from 325 patients who met the including standard. Statistical analysis was used to compare the differences of perioperative outcomes, histopathological results, and survival results between taTME and laTME groups. Results The mean time of pelvic operation in the taTME group was significantly shorter than in the laTME group (62.2 ± 14.2 mins vs 81.1 ± 18.9 mins, P = 0.003). The complication incidence rate and the rate of protective loop ileostomy in the taTME group were significantly lower than those in the laTME group (19.8% vs 38.7%, P = 0.003 and 70.8% vs 92.5%, P < 0.001). In long-term result, there was no significant difference between the two groups for 3-year OS (87.3% vs 85.4%, P = 0.86) or 3-year DFS (74.9% vs 70.1%, P = 0.92). The 2-year cumulative local recurrence rate was similar between the two groups (1.1% vs 5.8%, P = 0.22). Conclusion This study demonstrated that taTME might reduce the incidence of postoperative complications, especially of anastomotic leakage in these “challenging” patients. taTME may be considered to have clear advantages for “challenging” patients.","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46633089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Characterization of Desmoglein 3 (DSG3) as a Sensitive and Specific Marker for Esophageal Squamous Cell Carcinoma desmoglin 3 (DSG3)作为食管鳞状细胞癌敏感特异性标志物的研究

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice

Pub Date : 2022-02-24 DOI: 10.1155/2022/2220940

Zhikai Chi, J. Balani, P. Gopal, Suntrea Hammer, C. Lewis, Lan Peng

Although P40 and P63 are both sensitive and specific for routine esophageal squamous cell carcinoma (SCC) diagnosis, we recently showed that P40 and P63 immunoreactivities were significantly lower in well-differentiated SCC than those in higher grade tumors. Therefore, a novel esophageal SCC marker, ideally performing better in well-differentiated SCC, is still needed. We characterized desmoglein 3 (DSG3) immunohistochemistry in esophageal SCC, esophageal adenocarcinoma, small-cell lung carcinoma, and large B-cell lymphoma, alongside P40 and CK5/6. The World Health Organization classification was used to grade tumors as well-differentiated (WD), moderately differentiated (MD), or poorly differentiated (PD). There were 20 WD, 26 MD, and 17 PD components among 39 esophageal SCC cases. All esophageal SCC components showed significant DSG3 immunoreactivity (mean, 80%; range, 30%–100%), and the proportions of DSG3 immunoreactive cells were higher in the WD and MD components than in the PD components. No esophageal adenocarcinoma cases showed more than 10% DSG3 immunoreactivity with only weak cytoplasmic staining. With a 5% immunoreactivity cutoff, DSG3 positivity was 100% in all 63 SCC components, 18% in adenocarcinoma cases, and 0% in small-cell lung carcinoma or large B-cell lymphoma cases. The overall DSG3 specificity was 94%. To the best of our knowledge, this is the first study to characterize DSG3 as a sensitive and specific marker for esophageal SCC.

尽管P40和P63对常规食管鳞状细胞癌（SCC）的诊断既敏感又特异，但我们最近发现，高分化SCC中P40和P63的免疫反应性明显低于高级别肿瘤。因此，仍然需要一种新的食管鳞状细胞癌标志物，理想的是在高分化鳞状细胞癌中表现更好。我们对结蛋白3（DSG3）在食管鳞状细胞癌、食管腺癌、小细胞肺癌和大B细胞淋巴瘤以及P40和CK5/6中的免疫组织化学进行了表征。世界卫生组织的分类用于将肿瘤分为高分化（WD）、中分化（MD）或低分化（PD）。39例食管鳞状细胞癌中有20个WD、26个MD和17个PD成分。所有食管SCC组分均显示出显著的DSG3免疫反应性（平均80%；范围30%-100%），WD和MD组分中DSG3免疫细胞的比例高于PD组分。没有食管腺癌病例显示出超过10%的DSG3免疫反应性，只有微弱的细胞质染色。在5%的免疫反应性截止值下，DSG3在所有63种SCC成分中的阳性率为100%，在腺癌病例中为18%，在小细胞肺癌或大B细胞淋巴瘤病例中为0%。DSG3的总体特异性为94%。据我们所知，这是首次将DSG3定性为食管SCC的敏感和特异性标志物。

{"title":"Characterization of Desmoglein 3 (DSG3) as a Sensitive and Specific Marker for Esophageal Squamous Cell Carcinoma","authors":"Zhikai Chi, J. Balani, P. Gopal, Suntrea Hammer, C. Lewis, Lan Peng","doi":"10.1155/2022/2220940","DOIUrl":"https://doi.org/10.1155/2022/2220940","url":null,"abstract":"Although P40 and P63 are both sensitive and specific for routine esophageal squamous cell carcinoma (SCC) diagnosis, we recently showed that P40 and P63 immunoreactivities were significantly lower in well-differentiated SCC than those in higher grade tumors. Therefore, a novel esophageal SCC marker, ideally performing better in well-differentiated SCC, is still needed. We characterized desmoglein 3 (DSG3) immunohistochemistry in esophageal SCC, esophageal adenocarcinoma, small-cell lung carcinoma, and large B-cell lymphoma, alongside P40 and CK5/6. The World Health Organization classification was used to grade tumors as well-differentiated (WD), moderately differentiated (MD), or poorly differentiated (PD). There were 20 WD, 26 MD, and 17 PD components among 39 esophageal SCC cases. All esophageal SCC components showed significant DSG3 immunoreactivity (mean, 80%; range, 30%–100%), and the proportions of DSG3 immunoreactive cells were higher in the WD and MD components than in the PD components. No esophageal adenocarcinoma cases showed more than 10% DSG3 immunoreactivity with only weak cytoplasmic staining. With a 5% immunoreactivity cutoff, DSG3 positivity was 100% in all 63 SCC components, 18% in adenocarcinoma cases, and 0% in small-cell lung carcinoma or large B-cell lymphoma cases. The overall DSG3 specificity was 94%. To the best of our knowledge, this is the first study to characterize DSG3 as a sensitive and specific marker for esophageal SCC.","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47998626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The Influence of Radiological “Disappearing Lesions” on the Efficacy and Prognosis of Patients with Colorectal Liver Metastases Undergoing Conversion Therapy 放射学“消失病灶”对接受转化治疗的结直肠肝转移患者疗效和预后的影响

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice

Pub Date : 2022-02-22 DOI: 10.1155/2022/2200598

Z. Song, Dong-ming Yang, Yang Liu, Yong Cheng

Purpose The purpose of the current study was to analyze the influence of radiological “disappearing liver metastasis” (DLM) on the efficacy and prognosis of patients with colorectal liver metastases (CRLM) undergoing conversion therapy. Methods Patients with CRLM by the multidisciplinary team (MDT) of the First Affiliated Hospital of Chongqing Medical University were retrospectively enrolled from January 2014 to January 2021. The relationship between the occurrence and recurrence of DLM and different clinical factors was analyzed. Results Thirty-five of the 113 patients (31.0%) with initially unresectable CRLM developed DLM, and of the 361 lesions, 177 disappeared (49.0%). Within 6 months, 6-12 months, and 12-24 months groups, the recurrence rate was 3.4%, 16.8%, and 34.8%, but there is no recurrence in after 24 months group. There was a statistical difference between chemotherapy alone and chemotherapy combined with the targeted therapy group on the occurrence of DLM (58.3% vs. 37.1%, P < 0.001). There were significant differences between <5 mm group and >10 mm group on occurrence of DLM（76.7% vs. 30.4%, P < 0.001) and between 5-10 mm group and >10 mm group also (70.0% vs. 30.4%, P < 0.001). Through univariate and multivariate analyses, it was concluded that age (P = 0.026, 95%CI = 3.690) and treatment regimens (P = 0.033, 95%CI = 2.703) had a significant influence on the progression-free survival (PFS) time of DLM. Conclusion Younger patients, who use chemotherapy alone to achieve a therapeutic effect, might have better survival benefits when the lesions do not progress within 2 years after the appearance of DLMs.

目的本研究的目的是分析放射性“消失性肝转移”（DLM）对接受转化治疗的结直肠癌肝转移（CRLM）患者疗效和预后的影响。方法对重庆医科大学第一附属医院多学科团队2014年1月至2021年1月收治的CRLM患者进行回顾性分析。分析DLM的发生和复发与不同临床因素的关系。结果113例CRLM患者中有35例（31.0%）发生了DLM，361例中177例（49.0%）消失。在6个月、6-12个月和12-24个月内，复发率分别为3.4%、16.8%和34.8%，但24个月后无复发。在DLM的发生率上，单独化疗和化疗联合靶向治疗组之间有统计学差异（58.3%对37.1%，P＜0.001） mm组DLM发生率（76.7%对30.4%，P＜0.001），5-10 mm组与>10 通过单因素和多因素分析，得出年龄（P=0.026，95%CI=3.690）和治疗方案（P=0.033，95%CI=2.703）对DLM的无进展生存期（PFS）时间有显著影响。结论当DLMs出现后2年内病变没有进展时，单独使用化疗来达到治疗效果的年轻患者可能具有更好的生存效益。

{"title":"The Influence of Radiological “Disappearing Lesions” on the Efficacy and Prognosis of Patients with Colorectal Liver Metastases Undergoing Conversion Therapy","authors":"Z. Song, Dong-ming Yang, Yang Liu, Yong Cheng","doi":"10.1155/2022/2200598","DOIUrl":"https://doi.org/10.1155/2022/2200598","url":null,"abstract":"Purpose The purpose of the current study was to analyze the influence of radiological “disappearing liver metastasis” (DLM) on the efficacy and prognosis of patients with colorectal liver metastases (CRLM) undergoing conversion therapy. Methods Patients with CRLM by the multidisciplinary team (MDT) of the First Affiliated Hospital of Chongqing Medical University were retrospectively enrolled from January 2014 to January 2021. The relationship between the occurrence and recurrence of DLM and different clinical factors was analyzed. Results Thirty-five of the 113 patients (31.0%) with initially unresectable CRLM developed DLM, and of the 361 lesions, 177 disappeared (49.0%). Within 6 months, 6-12 months, and 12-24 months groups, the recurrence rate was 3.4%, 16.8%, and 34.8%, but there is no recurrence in after 24 months group. There was a statistical difference between chemotherapy alone and chemotherapy combined with the targeted therapy group on the occurrence of DLM (58.3% vs. 37.1%, P < 0.001). There were significant differences between <5 mm group and >10 mm group on occurrence of DLM（76.7% vs. 30.4%, P < 0.001) and between 5-10 mm group and >10 mm group also (70.0% vs. 30.4%, P < 0.001). Through univariate and multivariate analyses, it was concluded that age (P = 0.026, 95%CI = 3.690) and treatment regimens (P = 0.033, 95%CI = 2.703) had a significant influence on the progression-free survival (PFS) time of DLM. Conclusion Younger patients, who use chemotherapy alone to achieve a therapeutic effect, might have better survival benefits when the lesions do not progress within 2 years after the appearance of DLMs.","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44199166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study 抗反流粘膜切除术治疗严重胃食管反流病的疗效评价：一项初步研究的中期结果

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice

Pub Date : 2022-02-21 DOI: 10.1155/2022/1606944

A. Laquière, F. Trottier-Tellier, R. Ureña-Campos, P. Lienne, L. Lecomte, M. Katsogiannou, G. Pénaranda, C. Boustière

Background Antireflux mucosectomy, a new endoscopic treatment for gastroesophageal reflux disease, consists of endoscopic mucosal resection at the esophagogastric junction. This study aim was to evaluate the medium-term efficacy of the antireflux mucosectomy technique for patients with severe gastroesophageal reflux disease symptoms (proton pump inhibitor treatment-dependent or proton pump inhibitor treatment-resistant gastroesophageal reflux disease). Methods Between January 2017 and June 2018, 13 patients with severe gastroesophageal reflux disease without hiatal hernia, with positive pH reflux, were included in this monocentric prospective pilot study. The primary outcome was clinical success, defined by improvement evaluated by the Gastroesophageal Reflux Disease Health Related Quality of Life Questionnaire at 24 months. Secondary outcomes were technical success, decreased use of proton pump inhibitors, patient satisfaction, and adverse events. Results Thirteen patients [females = 8 (62%)], mean age 59 (range, 54-68), were included. The antireflux mucosectomy procedure had technical success in all patients. At 24 months, for 11 patients, gastroesophageal reflux disease symptoms were significantly improved, and mean gastroesophageal reflux disease score decreased from 33 (range, 26-42) to 3 (range, 0-7) (p = 0.001). Ninety-one percent (n = 10) of patients had a lower proton pump inhibitor intake at 24 months. One patient had 3 endoscopic balloon dilatations for EGJ stenosis, two patients had melena ten days after procedure, and seven patients had thoracic or abdominal pain. Patient's satisfaction at 24 months was 81%. Conclusions In patients with severe gastroesophageal reflux disease, despite occurrence of several short-term adverse events, antireflux mucosectomy seemed effective in improving gastroesophageal reflux disease symptoms at 24 months. This trial is registered with ClinicalTrials: NCT03357809.

背景抗反流粘膜切除术是一种新的内镜治疗胃食管反流疾病的方法，包括食管胃交界处的内镜粘膜切除术。本研究的目的是评估抗反流粘膜切除术对有严重胃食管反流疾病症状（质子泵抑制剂治疗依赖性或质子泵抑制剂耐药性胃食管反流病）患者的中期疗效。方法在2017年1月至2018年6月期间，13名无裂孔疝、pH值反流阳性的严重胃食管反流病患者被纳入这项单中心前瞻性试点研究。主要结果是临床成功，定义为24个月时通过胃食管反流病健康相关生活质量问卷评估的改善。次要结果是技术成功、质子泵抑制剂使用减少、患者满意度和不良事件。结果13例患者[女性=8例（62%）]，平均年龄59岁（范围54-68岁）。抗反流粘膜切除术在所有患者中都取得了技术上的成功。24个月时，11名患者的胃食管反流疾病症状显著改善，平均胃食管反流病评分从33分（26-42分）降至3分（0-7分）（p=0.001）。91%（n=10）的患者在24个月内质子泵抑制剂摄入量较低。1名患者因EGJ狭窄进行了3次内镜球囊扩张，2名患者在手术后10天出现黑便，7名患者出现胸痛或腹痛。患者在24个月时的满意度为81%。结论在严重胃食管反流病患者中，尽管发生了一些短期不良事件，但抗反流粘膜切除术在24个月时似乎能有效改善胃食管反流病症状。该试验已在临床试验注册：NCT03357809。

{"title":"Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study","authors":"A. Laquière, F. Trottier-Tellier, R. Ureña-Campos, P. Lienne, L. Lecomte, M. Katsogiannou, G. Pénaranda, C. Boustière","doi":"10.1155/2022/1606944","DOIUrl":"https://doi.org/10.1155/2022/1606944","url":null,"abstract":"Background Antireflux mucosectomy, a new endoscopic treatment for gastroesophageal reflux disease, consists of endoscopic mucosal resection at the esophagogastric junction. This study aim was to evaluate the medium-term efficacy of the antireflux mucosectomy technique for patients with severe gastroesophageal reflux disease symptoms (proton pump inhibitor treatment-dependent or proton pump inhibitor treatment-resistant gastroesophageal reflux disease). Methods Between January 2017 and June 2018, 13 patients with severe gastroesophageal reflux disease without hiatal hernia, with positive pH reflux, were included in this monocentric prospective pilot study. The primary outcome was clinical success, defined by improvement evaluated by the Gastroesophageal Reflux Disease Health Related Quality of Life Questionnaire at 24 months. Secondary outcomes were technical success, decreased use of proton pump inhibitors, patient satisfaction, and adverse events. Results Thirteen patients [females = 8 (62%)], mean age 59 (range, 54-68), were included. The antireflux mucosectomy procedure had technical success in all patients. At 24 months, for 11 patients, gastroesophageal reflux disease symptoms were significantly improved, and mean gastroesophageal reflux disease score decreased from 33 (range, 26-42) to 3 (range, 0-7) (p = 0.001). Ninety-one percent (n = 10) of patients had a lower proton pump inhibitor intake at 24 months. One patient had 3 endoscopic balloon dilatations for EGJ stenosis, two patients had melena ten days after procedure, and seven patients had thoracic or abdominal pain. Patient's satisfaction at 24 months was 81%. Conclusions In patients with severe gastroesophageal reflux disease, despite occurrence of several short-term adverse events, antireflux mucosectomy seemed effective in improving gastroesophageal reflux disease symptoms at 24 months. This trial is registered with ClinicalTrials: NCT03357809.","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45434922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Endoscopic Resection for Small Gastric Gastrointestinal Stromal Tumors in Elderly Patients. 内镜下切除老年胃胃肠道间质小肿瘤的疗效和安全性。

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice

Pub Date : 2022-01-01 DOI: 10.1155/2022/8415913

Changzhou Cai, Jinpu Yang, Mengting Ren, Lu Lv, Xinxin Zhou, Mosang Yu, Feng Ji

Background: Gastrointestinal stromal tumors (GISTs) are prevalent in elderly patients. Endoscopic resection has become popular for treating small (≤5 cm) gastric GISTs. However, little is known about the outcomes of endoscopic resection in elderly patients.

Aim: To assess the efficacy and safety of endoscopic resection for small (≤5 cm) gastric GISTs in elderly patients (≥65 years old).

Methods: A total of 260 patients (265 lesions) with gastric GISTs treated via endoscopic resection from January 2011 to May 2020 were retrospectively analyzed. Among them, 65 patients were ≥65 years old (elderly group), and 195 patients were <65 years old (nonelderly group). Clinicopathological characteristics, postoperative complications, and tumor recurrence rates between the two age groups were compared.

Results: A total of 260 patients with primary small (≤5 cm) gastric GISTs were treated with endoscopic resection. The median ages of the elderly and nonelderly groups were 68 (range 65-83) years and 55 (range 32-64) years, respectively. Elderly patients showed a higher incidence of comorbidities compared with nonelderly patients (61.5% versus 32.3%s, respectively; p < 0.001). All elderly patients and 99.0% of nonelderly patients underwent en bloc resection; only two nonelderly patients received piecemeal resection. No significant differences were found regarding postoperative complications or tumor recurrence rates between the two groups.

Conclusions: Although elderly patients had more comorbidities than nonelderly patients, both groups had similar postoperative complications and recurrence rates. We suggest that endoscopic resection performed by experienced endoscopists is safe and effective for treating small (≤5 cm) gastric GISTs in elderly patients.

背景:胃肠道间质瘤(gist)在老年患者中普遍存在。内镜切除已成为治疗小(≤5 cm)胃gist的常用方法。然而，对老年患者内镜切除的结果知之甚少。目的:评价内镜下切除老年(≥65岁)小(≤5 cm)胃间质瘤的疗效和安全性。方法:回顾性分析2011年1月至2020年5月经内镜切除的胃间质瘤患者260例(265个病灶)。其中65例患者年龄≥65岁(老年组)，195例患者年龄≥65岁。结果:260例原发性胃小(≤5 cm)胃肠道间质瘤患者行内镜切除。老年组和非老年组的中位年龄分别为68岁(65 ~ 83岁)和55岁(32 ~ 64岁)。老年患者的合并症发生率高于非老年患者(分别为61.5%和32.3%);P < 0.001)。所有老年患者和99.0%的非老年患者均行整体切除;只有2例非老年患者接受了局部切除。两组术后并发症及肿瘤复发率无明显差异。结论:虽然老年患者的合并症多于非老年患者，但两组患者术后并发症和复发率相似。我们认为由经验丰富的内镜医师进行内镜切除对于治疗老年患者小(≤5 cm)胃间质瘤是安全有效的。

{"title":"Efficacy and Safety of Endoscopic Resection for Small Gastric Gastrointestinal Stromal Tumors in Elderly Patients.","authors":"Changzhou Cai, Jinpu Yang, Mengting Ren, Lu Lv, Xinxin Zhou, Mosang Yu, Feng Ji","doi":"10.1155/2022/8415913","DOIUrl":"https://doi.org/10.1155/2022/8415913","url":null,"abstract":"Background: Gastrointestinal stromal tumors (GISTs) are prevalent in elderly patients. Endoscopic resection has become popular for treating small (≤5 cm) gastric GISTs. However, little is known about the outcomes of endoscopic resection in elderly patients.Aim: To assess the efficacy and safety of endoscopic resection for small (≤5 cm) gastric GISTs in elderly patients (≥65 years old).Methods: A total of 260 patients (265 lesions) with gastric GISTs treated via endoscopic resection from January 2011 to May 2020 were retrospectively analyzed. Among them, 65 patients were ≥65 years old (elderly group), and 195 patients were <65 years old (nonelderly group). Clinicopathological characteristics, postoperative complications, and tumor recurrence rates between the two age groups were compared.Results: A total of 260 patients with primary small (≤5 cm) gastric GISTs were treated with endoscopic resection. The median ages of the elderly and nonelderly groups were 68 (range 65-83) years and 55 (range 32-64) years, respectively. Elderly patients showed a higher incidence of comorbidities compared with nonelderly patients (61.5% versus 32.3%s, respectively; p < 0.001). All elderly patients and 99.0% of nonelderly patients underwent en bloc resection; only two nonelderly patients received piecemeal resection. No significant differences were found regarding postoperative complications or tumor recurrence rates between the two groups.Conclusions: Although elderly patients had more comorbidities than nonelderly patients, both groups had similar postoperative complications and recurrence rates. We suggest that endoscopic resection performed by experienced endoscopists is safe and effective for treating small (≤5 cm) gastric GISTs in elderly patients.","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2022 ","pages":"8415913"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10615139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gel Immersion Endoscopic Mucosal Resection (EMR) for Superficial Nonampullary Duodenal Epithelial Tumors May Reduce Procedure Time Compared with Underwater EMR (with Video). 凝胶浸泡内镜下粘膜切除术(EMR)治疗浅表非壶腹性十二指肠上皮肿瘤与水下EMR(带视频)相比可缩短手术时间。

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice

Pub Date : 2022-01-01 DOI: 10.1155/2022/2040792

Takeshi Yamashina, Masaaki Shimatani, Yu Takahashi, Masahiro Takeo, Natsuko Saito, Hironao Matsumoto, Takeshi Kasai, Masataka Kano, Kimi Sumimoto, Toshiyuki Mitsuyama, Hiroyuki Marusawa, Akiyoshi Nishio, Takafumi Yuba, Toshihito Seki, Makoto Naganuma

Materials and methods: This was a retrospective cohort study conducted in two municipal hospitals. We identified 24 patients with SNADETs of 3-18 mm in diameter who underwent UEMR or GIEMR. One lesion was excluded from the analysis because it was found to be in the stomach after surgery. The primary outcome was procedure time.

Results: GIEMR significantly reduced the procedure time compared with UEMR (5 min vs. 10 min, P = 0.016). There was no significant difference between the UEMR and GIEMR groups for en bloc resection rate (93% vs. 100%, P = 1.0) and R0 resection rate (57% vs. 80%, P = 0.39). No serious complications were observed in either group.

Conclusions: GIEMR of SNADET has the potential to reduce procedure time compared with UEMR and may be particularly effective in areas where immersion in water is difficult.

材料和方法:本研究是在两家市立医院进行的回顾性队列研究。我们确定了24例直径为3- 18mm的snadet患者，他们接受了UEMR或GIEMR。有一个病变被排除在分析之外，因为手术后发现它在胃里。主要观察指标为手术时间。结果:与UEMR相比，GIEMR显著缩短了手术时间(5 min vs. 10 min, P = 0.016)。UEMR组和GIEMR组的整体切除率(93%对100%，P = 1.0)和R0切除率(57%对80%，P = 0.39)无显著差异。两组均未见严重并发症。结论:与UEMR相比，SNADET的GIEMR有可能缩短手术时间，并且在难以浸泡在水中的区域可能特别有效。

{"title":"Gel Immersion Endoscopic Mucosal Resection (EMR) for Superficial Nonampullary Duodenal Epithelial Tumors May Reduce Procedure Time Compared with Underwater EMR (with Video).","authors":"Takeshi Yamashina, Masaaki Shimatani, Yu Takahashi, Masahiro Takeo, Natsuko Saito, Hironao Matsumoto, Takeshi Kasai, Masataka Kano, Kimi Sumimoto, Toshiyuki Mitsuyama, Hiroyuki Marusawa, Akiyoshi Nishio, Takafumi Yuba, Toshihito Seki, Makoto Naganuma","doi":"10.1155/2022/2040792","DOIUrl":"https://doi.org/10.1155/2022/2040792","url":null,"abstract":"Materials and methods: This was a retrospective cohort study conducted in two municipal hospitals. We identified 24 patients with SNADETs of 3-18 mm in diameter who underwent UEMR or GIEMR. One lesion was excluded from the analysis because it was found to be in the stomach after surgery. The primary outcome was procedure time.Results: GIEMR significantly reduced the procedure time compared with UEMR (5 min vs. 10 min, P = 0.016). There was no significant difference between the UEMR and GIEMR groups for en bloc resection rate (93% vs. 100%, P = 1.0) and R0 resection rate (57% vs. 80%, P = 0.39). No serious complications were observed in either group.Conclusions: GIEMR of SNADET has the potential to reduce procedure time compared with UEMR and may be particularly effective in areas where immersion in water is difficult.","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2022 ","pages":"2040792"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9266873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

The Effect and Related Mechanism of Action of Astragalus Compatible with Curcumin against Colon Cancer Metastasis in Mice. 黄芪与姜黄素配伍抗小鼠结肠癌转移的作用及相关机制。

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice

Pub Date : 2022-01-01 DOI: 10.1155/2022/9578307

Jiafei Wu, Decai Tang

Colon cancer (CC) is the third most common tumor worldwide. Colon carcinogenesis is strongly linked to inflammation. The initiation and progression of colon cancer may be influenced by epigenetic processes. Cancer metastasis is a multistep process involving several genes and their products. During tumor metastasis, cancer cells first enhance their proliferative capacity by lowering autophagy and apoptosis, and then, their capacity is stimulated by boosting tumors' ability to take nutrients from the outside via angiogenesis. Traditional treatment focuses on eliminating tumor cells by triggering cell death or activating the immune system, which often results in side effects or chemoresistance recurrence. On the contrary, Chinese medicine theory considers the patient's entire inner system and aids in tumor shrinkage while also taking into account the mouse' general health. Because many Chinese herbal medicines (CHM) are consumed as food, using edible CHMs as a diet resource therapy for colon cancer treatment is a viable option. Two traditional Chinese herbs, Astragalus membranaceus and Curcuma zedoaria, are commonly utilized jointly in colon cancer preventive therapy. As a result, the anticancer effect of astragalus and curcumin (AC) on colon cancer suppression in an 18-week AOM-DSS colon cancer mouse model is investigated in this research. These findings may offer a scientific foundation for investigating colon cancer diagnostic biomarkers and therapeutic application of AC in colon cancer treatment. These studies also highlighted the potential effect and mechanism of AC in the treatment of colon cancer, as well as providing insight into how to effectively use it.

结肠癌(CC)是全球第三大常见肿瘤。结肠癌的发生与炎症密切相关。结肠癌的发生和发展可能受到表观遗传过程的影响。肿瘤转移是一个涉及多个基因及其产物的多步骤过程。在肿瘤转移过程中，癌细胞首先通过降低自噬和凋亡来增强其增殖能力，然后通过血管生成增强肿瘤从外界吸收营养的能力来刺激其增殖能力。传统的治疗侧重于通过触发细胞死亡或激活免疫系统来消除肿瘤细胞，这往往导致副作用或化疗耐药复发。相反，中医理论考虑了患者的整个内部系统，有助于肿瘤的缩小，同时也考虑了小鼠的总体健康状况。由于许多中草药作为食物被食用，使用可食用中草药作为治疗结肠癌的饮食资源疗法是一种可行的选择。两种传统中药黄芪和莪术常被联合用于结肠癌的预防治疗。因此，本研究在18周的AOM-DSS结肠癌小鼠模型中研究黄芪和姜黄素(AC)对结肠癌的抑制作用。这些发现可能为进一步研究结肠癌的诊断生物标志物及AC在结肠癌治疗中的应用提供科学依据。这些研究也突出了AC治疗结肠癌的潜在作用和机制，并为如何有效地使用它提供了见解。

{"title":"The Effect and Related Mechanism of Action of Astragalus Compatible with Curcumin against Colon Cancer Metastasis in Mice.","authors":"Jiafei Wu, Decai Tang","doi":"10.1155/2022/9578307","DOIUrl":"https://doi.org/10.1155/2022/9578307","url":null,"abstract":"Colon cancer (CC) is the third most common tumor worldwide. Colon carcinogenesis is strongly linked to inflammation. The initiation and progression of colon cancer may be influenced by epigenetic processes. Cancer metastasis is a multistep process involving several genes and their products. During tumor metastasis, cancer cells first enhance their proliferative capacity by lowering autophagy and apoptosis, and then, their capacity is stimulated by boosting tumors' ability to take nutrients from the outside via angiogenesis. Traditional treatment focuses on eliminating tumor cells by triggering cell death or activating the immune system, which often results in side effects or chemoresistance recurrence. On the contrary, Chinese medicine theory considers the patient's entire inner system and aids in tumor shrinkage while also taking into account the mouse' general health. Because many Chinese herbal medicines (CHM) are consumed as food, using edible CHMs as a diet resource therapy for colon cancer treatment is a viable option. Two traditional Chinese herbs, Astragalus membranaceus and Curcuma zedoaria, are commonly utilized jointly in colon cancer preventive therapy. As a result, the anticancer effect of astragalus and curcumin (AC) on colon cancer suppression in an 18-week AOM-DSS colon cancer mouse model is investigated in this research. These findings may offer a scientific foundation for investigating colon cancer diagnostic biomarkers and therapeutic application of AC in colon cancer treatment. These studies also highlighted the potential effect and mechanism of AC in the treatment of colon cancer, as well as providing insight into how to effectively use it.","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2022 ","pages":"9578307"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10417656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Analysis of Hepatic Artery Infusion (HAI) Chemotherapy Using Randomized Trials of Floxuridine (FUDR) for Colon Cancer Patients with Multiple Liver Metastases. 肝动脉输注(HAI)化疗氟尿定(FUDR)治疗结肠癌多发肝转移患者的随机试验分析

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice

Pub Date : 2022-01-01 DOI: 10.1155/2022/3546455

Yuanming Li

Colorectal cancer (CRC) is one of the leading causes of cancer-related death, with most of the people who have the disease developing numerous liver metastases. Sixty percent of colon cancer patients have liver metastases. Only 25% of those with resectable hepatic metastases are alive, and recurrence occurs in nearly half of these cases. Regardless of the fact that left-sided cancer has a higher rate of liver metastases, past study reveals that left- and right-sided liver metastatic colon cancer patients have different survival rates. Hepatic artery infusion (HAI) combined with systemic chemotherapy is a treatment option for patients with unresectable liver-only or liver-dominant colon liver metastases. Although HAI has only been performed in a few locations previously, this study used randomized trials of floxuridine (FUDR) to characterize patient selection and first perioperative results during the deployment of a new HAI program. In this research, we also looked at the technical aspects of placing implantable pumps and catheters for HAI chemotherapy, as well as the efficacy, morbidity, and outcomes of this therapy in colon cancer patients with numerous liver metastases. The parameters like toxicity, overall survival rate, response rate, and progression-free response for the suggested therapy are also analyzed. These findings have important implications for colon cancer adjuvant HAI chemotherapy.

结直肠癌(CRC)是癌症相关死亡的主要原因之一，大多数患有这种疾病的人都会发生大量的肝转移。60%的结肠癌患者有肝转移。在可切除的肝转移患者中，只有25%的患者存活，其中近一半的患者会复发。尽管左侧肿瘤的肝转移率更高，但过去的研究表明，左侧和右侧肝转移结肠癌患者的生存率不同。肝动脉输注(HAI)联合全身化疗是不可切除的单肝或肝脏显性结肠肝转移患者的一种治疗选择。虽然HAI以前只在少数地方进行过，但本研究使用氟尿定(FUDR)的随机试验来描述患者选择和新HAI计划部署期间的首次围手术期结果。在这项研究中，我们还研究了在HAI化疗中放置植入式泵和导管的技术方面，以及这种治疗在有大量肝转移的结肠癌患者中的疗效、发病率和结果。分析了建议治疗的毒性、总生存率、反应率和无进展反应等参数。这些发现对结肠癌辅助HAI化疗具有重要意义。

{"title":"Analysis of Hepatic Artery Infusion (HAI) Chemotherapy Using Randomized Trials of Floxuridine (FUDR) for Colon Cancer Patients with Multiple Liver Metastases.","authors":"Yuanming Li","doi":"10.1155/2022/3546455","DOIUrl":"https://doi.org/10.1155/2022/3546455","url":null,"abstract":"Colorectal cancer (CRC) is one of the leading causes of cancer-related death, with most of the people who have the disease developing numerous liver metastases. Sixty percent of colon cancer patients have liver metastases. Only 25% of those with resectable hepatic metastases are alive, and recurrence occurs in nearly half of these cases. Regardless of the fact that left-sided cancer has a higher rate of liver metastases, past study reveals that left- and right-sided liver metastatic colon cancer patients have different survival rates. Hepatic artery infusion (HAI) combined with systemic chemotherapy is a treatment option for patients with unresectable liver-only or liver-dominant colon liver metastases. Although HAI has only been performed in a few locations previously, this study used randomized trials of floxuridine (FUDR) to characterize patient selection and first perioperative results during the deployment of a new HAI program. In this research, we also looked at the technical aspects of placing implantable pumps and catheters for HAI chemotherapy, as well as the efficacy, morbidity, and outcomes of this therapy in colon cancer patients with numerous liver metastases. The parameters like toxicity, overall survival rate, response rate, and progression-free response for the suggested therapy are also analyzed. These findings have important implications for colon cancer adjuvant HAI chemotherapy.","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2022 ","pages":"3546455"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10417644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Systematic Therapy for Gastrointestinal Tumors 胃肠肿瘤的系统治疗

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice

Pub Date : 2021-10-28 DOI: 10.1155/2021/9821034

Zhongguang Luo, Qingyuan Yang, Zhihua Kang

引用次数: 0